Amarin Corp Plcuk (AMRN) Retained Earnings (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Retained Earnings of -$1.7 billion for Q1 2026, down 2.0% year-over-year from -$1.8 billion in Q1 2025, and down 0.62% quarter-over-quarter from -$1.7 billion in Q4 2025.
Amarin Corp Plcuk (AMRN) Retained Earnings (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Retained Earnings data on file, last reported at -$1.7 billion in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$1.7 billion, down 2.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.7 billion (down 2.0% YoY), and the FY2025 annual result was -$1.7 billion, down 2.33% from the prior year.
- Retained Earnings fell to -$1.7 billion in Q1 2026 per AMRN's latest filing, from -$1.7 billion in the prior quarter.
- Over five years, Retained Earnings peaked at -$1.5 billion in Q1 2022 and troughed at -$1.7 billion in Q1 2026.
- A 5-year average of -$1.6 billion and a median of -$1.6 billion in 2024 frame the typical range for Retained Earnings.
- On a YoY basis, Retained Earnings climbed as much as 1.55% in 2022 and fell as far as 7.44% in 2022.
- A 5-year view of Retained Earnings shows it stood at -$1.5 billion in 2022, then decreased by 3.87% to -$1.6 billion in 2023, then slipped by 5.18% to -$1.7 billion in 2024, then dropped by 2.33% to -$1.7 billion in 2025, then retreated by 0.62% to -$1.7 billion in 2026.
- Business Quant data shows AMRN's Retained Earnings at -$1.7 billion in Q1 2026, -$1.7 billion in Q4 2025, and -$1.7 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 1.90 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 29.51 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -14.83 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -17.87 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.37 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | -1.72 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.72 Bn |
| Dec 31, 2025 | -1.71 Bn |
| Sep 30, 2025 | -1.71 Bn |
| Jun 30, 2025 | -1.70 Bn |
| Mar 31, 2025 | -1.68 Bn |
| Dec 31, 2024 | -1.67 Bn |
| Sep 30, 2024 | -1.62 Bn |
| Jun 30, 2024 | -1.59 Bn |
| Mar 31, 2024 | -1.60 Bn |
| Dec 31, 2023 | -1.59 Bn |
| Sep 30, 2023 | -1.58 Bn |
| Jun 30, 2023 | -1.56 Bn |
| Mar 31, 2023 | -1.54 Bn |
| Dec 31, 2022 | -1.53 Bn |
| Sep 30, 2022 | -1.53 Bn |
| Jun 30, 2022 | -1.52 Bn |
| Mar 31, 2022 | -1.45 Bn |
| Dec 31, 2021 | -1.42 Bn |
| Sep 30, 2021 | -1.44 Bn |
| Jun 30, 2021 | -1.42 Bn |